MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietary BEPO® technology, licensed to Teva as SteadyTeqTM. The findings were presented at Psych Congress 2026, held from September 15 to 19 in New Orleans, Louisiana. Teva presented new post hoc analyses from the Phase 3 SOLARIS trial evaluating its investigational once-monthly subcutaneous olanzapine LAI